Journal of Medicinal Chemistry · 2014 · 41 citations · 13 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationAntiparasitic Drug ResistanceHit-to-lead OptimizationLead Compound DesignLead DiscoveryMalariaPharmacokinetic OptimizationAdme ProfilingAntimalarial AgentsAntimalarial ChemotherapyAntimalarial Drug DevelopmentMalaria ParasitesMalaria ResistancePlasmodium FalciparumTreatment Of Malaria
From the phenotypic screening of the AstraZeneca corporate compound collection, N-aryl-2-aminobenzimidazoles have emerged as novel hits against the asexual blood stage of Plasmodium falciparum (Pf). Medicinal chemistry optimization of the potency against Pf and ADME properties resulted in the identification of 12 as a lead molecule. Compound 12 was efficacious in the P. berghei (Pb) model of malaria. This compound displayed an excellent pharmacokinetic profile with a long half-life (19 h) in rat blood. This profile led to an extended survival of animals for over 30 days following a dose of 50 mg/kg in the Pb malaria model. Compound 12 retains its potency against a panel of Pf isolates with known mechanisms of resistance. The fast killing observed in the in vitro parasite reduction ratio (PRR) assay coupled with the extended survival highlights the promise of this novel chemical class for the treatment of malaria.
13
A molecular marker of artemisinin-resistant Plasmodium falciparum malaria
Frédéric Ariey, Benoît Witkowski, Chanaki Amaratunga et al. · Nature · 2013 · 2.2K citations · Full text
Spiroindolones, a Potent Compound Class for the Treatment of Malaria
Matthias Rottmann, Case W. McNamara, Bryan K. S. Yeung et al. · Science · 2010 · 1.2K citations · Full text
Targeting Plasmodium PI(4)K to eliminate malaria
Case W. McNamara, Chek Shik Lim, Siau Hoi Lim et al. · Nature · 2013 · 426 citations · Full text